Skip to main content Accessibility help

PUFA-derived endocannabinoids: an overview

  • Maria Grazia Cascio (a1)


Following on from the discovery of cannabinoid receptors, of their endogenous agonists (endocannabinoids) and of the biosynthetic and metabolic enzymes of the endocannabinoids, significant progress has been made towards the understanding of the role of the endocannabinoid system in both physiological and pathological conditions. Endocannabinoids are mainly n-6 long-chain PUFA (LCPUFA) derivatives that are synthesised by neuronal cells and inactivated via a two-step process that begins with their transport from the extracellular to the intracellular space and culminates in their intracellular degradation by hydrolysis or oxidation. Although the enzymes responsible for the biosynthesis and metabolism of endocannabinoids have been well characterised, the processes involved in their cellular uptake are still a subject of debate. Moreover, little is yet known about the roles of endocannabinoids derived from n-3 LCPUFA such as EPA and DHA. Here, I provide an overview of what is currently known about the mechanisms for the biosynthesis and inactivation of endocannabinoids, together with a brief analysis of the involvement of the endocannabinoids in both food intake and obesity. Owing to limited space, recent reviews will be often cited instead of original papers.

  • View HTML
    • Send article to Kindle

      To send this article to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

      Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

      Find out more about the Kindle Personal Document Service.

      PUFA-derived endocannabinoids: an overview
      Available formats

      Send article to Dropbox

      To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

      PUFA-derived endocannabinoids: an overview
      Available formats

      Send article to Google Drive

      To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

      PUFA-derived endocannabinoids: an overview
      Available formats


Corresponding author

Corresponding author: M. G. Cascio, fax +44-1224-437465, email:


Hide All
1. Di Marzo, V, Bifulco, M & De Petrocellis, L (2004) The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3, 771784.
2. Devane, WA, Hanus, L, Breuer, A et al. (1992) Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258, 19461949.
3. Hanus, LO (2007) Discovery and isolation of anandamide and other endocannabinoids. Chem Biodivers 4, 18281841.
4. Di Marzo, V, Bisogno, T & De Petrocellis, L (2001) Anandamide: some like it hot. Trends Pharmacol Sci 22, 346349.
5. Smart, D, Gunthorpe, MJ, Jerman, JC et al. (2000) The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol 129, 227230.
6. Al-Hayani, A, Wease, KN, Ross, RA et al. (2001) The endogenous cannabinoid anandamide activates vanilloid receptors in the rat hippocampal slice. Neuropharmacology 41, 10001005.
7. Mechoulam, R, Ben-Shabat, S, Hanus, L et al. (1995) Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50, 8390.
8. Sugiura, T, Kondo, S, Sukagawa, A et al. (1995) 2-arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215, 8997.
9. Sigel, E, Baur, R, Rácz, I et al. (2011) The major central endocannabinoid directly acts at GABA(A) receptors. Proc Natl Acad Sci USA 108, 1815018155.
10. Hanus, L, Abu-Lafi, S, Fride, E et al. (2001) 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc Natl Acad Sci USA 98, 36623665.
11. Porter, AC, Sauer, J-M, Knierman, MD et al. (2002) Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J Pharmacol Exp Ther 301, 10201024.
12. De Petrocellis, L, Cascio, MG & Di Marzo, V (2004) The endocannabinoid system: a general view and latest additions. Br J Pharmacol 141, 765774.
13. De Petrocellis, L, Starowicz, K, Moriello, AS et al. (2007) Regulation of transient receptor potential channels of melastatin type 8 (TRPM8): effect of cAMP, cannabinoid CB1 receptors and endovanilloids. Exp Cell Res 313, 19111920.
14. Pertwee, RG (2005) The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J 7, E625E654.
15. Brown, I, Cascio, MG, Wahle, KWJ et al. (2010) Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines. Carcinogenesis 31, 15841591.
16. Bisogno, T, Delton Vandenbroucke, I, Milone, A et al. (1999) Biosynthesis and inactivation of N-arachidonoylethanolamine (anandamide) and N-docosahexaenoylethanolamine in bovine retina. Arch Biochem Biophys 370, 300307.
17. Sugiura, T, Kondo, S, Sukagawa, A et al. (1996) N-arachidonoylethanolamine (anandamide), an endogenous cannabinoid receptor ligand, and related lipid molecules in the nervous tissues. J Lipid Mediat Cell Signal 14, 5156.
18. Berger, A, Crozier, G, Bisogno, T et al. (2001) Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets (vol 98, pg 6402, 2001). Proc Natl Acad Sci USA 98, 76477647.
19. Maccarrone, M, Gasperi, V, Catani, MV et al. (2010b) The endocannabinoid system and its relevance for nutrition. Annu Rev Nutr 30, 423440.
20. Brown, I, Wahle, KWJ, Cascio, MG et al. (2011) Omega-3 N-acylethanolamines are endogenously synthesised from omega-3 fatty acids in different human prostate and breast cancer cell lines. Prostaglandins Leukot Essent Fatty Acids 85, 305310.
21. Brown, I, Cascio, MG, Rotondo, D et al. (2013) Cannabinoids and omega-3/6 endocannabinoids as cell death and anticancer modulators. Progr Lipid Res 52, 80109.
22. Mechoulam, R, Fride, E & Di Marzo, V (1998) Endocannabinoids. Eur J Pharmacol 359, 118.
23. Ben-Shabat, S, Fride, E, Sheskin, T et al. (1998) An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol 353, 2331.
24. Devane, WA, Dysarz, FA, Johnson, MR et al. (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34, 605613.
25. Matsuda, LA, Lolait, SJ, Brownstein, MJ et al. (1990) Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346, 561564.
26. Munro, S, Thomas, KL & Abu-Shaar, M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365, 6165.
27. Pertwee, RG (2006b) The pharmacology of cannabinoid receptors and their ligands: an overview. Int J Obes 30, S13S18.
28. Derkinderen, P, Ledent, C, Parmentier, M et al. (2001) Cannabinoids activate p38 mitogen-activated protein kinases through CB1 receptors in hippocampus. J Neurochem 77, 957960.
29. Gertsch, J, Schoop, R, Kuenzle, U et al. (2004) Echinacea alkylamides modulate TNF-alpha gene expression via cannabinoid receptor CB2 and multiple signal transduction pathways. FEBS Lett 577, 563569.
30. Howlett, AC, Barth, F, Bonner, TI et al. (2002) International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 54, 161202.
31. Pertwee, RG & Ross, RA (2002) Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 66, 101121.
32. Pertwee, R (2008) The therapeutic potential of drugs that target the endogenous cannabinoid system. Eur Neuropsychopharmacol 18, S170S171.
33. Battista, N, Di Tommaso, M, Bari, M et al. (2012) The endocannabinoid system: an overview. Front Behav Neurosci. 6, 17.
34. Price, MR, Baillie, GL, Thomas, A et al. (2005) Allosteric modulation of the cannabinoid CB1 receptor. Mol Pharmacol 68, 14841495.
35. Onaivi, ES, Ishiguro, H, Gong, JP et al. (2006) Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 1074, 514536.
36. Viscomi, MT, Oddi, S, Latini, L et al. (2009) Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway. J Neurosci 29, 45644570.
37. Gasperi, V, Dainese, E, Oddi, S et al. (2013) GPR55 and its interaction with membrane lipids: comparison with other endocannabinoid-binding receptors. Curr Med Chem 20, 6478.
38. Schmid, HHO, Schmid, PC & Natarajan, V (1996) The N-acylation-phosphodiesterase pathway and cell signalling. Chem Phys Lipids 80, 133142.
39. Schmid, HHO & Berdyshev, EV (2002) Cannabinoid receptor-inactive N-acylethanolamines and other fatty acid amides: metabolism and function. Prostaglandins Leukot Essent Fatty Acids 66, 363376.
40. Hansen, HS, Lauritzen, L, Moesgaard, B et al. (1998) Formation of N-acyl-phosphatidylethanolamines and N-acylethanolamines – proposed role in neurotoxicity. Biochem Pharmacol 55, 719725.
41. Sun, YX, Tsuboi, K, Okamoto, Y et al. (2004) Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D. Biochem J 380, 749756.
42. Simon, GM & Cravatt, BF (2006) Endocannabinoid biosynthesis proceeding through glycerophospho-N-acyl ethanolamine and a role for alpha/beta-hydrolase 4 in this pathway. J Biol Chem 281, 2646526472.
43. Liu, J, Wang, L, Harvey-White, J et al. (2006) A biosynthetic pathway for anandamide. Proc Natl Acad Sci USA 103, 1334513350.
44. Deutsch, DG & Chin, SA (1993) Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol 46, 791796.
45. Devane, WA & Axelrod, J (1994) Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes. Proc Natl Acad Sci USA 91, 66986701.
46. Ueda, N, Kurahashi, Y, Yamamoto, S et al. (1995) Partial purification and characterization of the porcine brain enzyme hydrolyzing and synthesizing anandamide. J Biol Chem 270, 2382323827.
47. Katayama, K, Ueda, N, Katoh, I et al. (1999) Equilibrium in the hydrolysis and synthesis of cannabimimetic anandamide demonstrated by a purified enzyme. Biochim Biophys Acta 1440, 205214.
48. Ueda, N, Tsuboi, K & Uyama, T (2010) Enzymological studies on the biosynthesis of N-acylethanolamines. Biochim Biophys Acta 1801, 12741285.
49. Bisogno, T, Howell, F, Williams, G et al. (2003) Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain. J Cell Biol 163, 463468.
50. Williams, EJ, Walsh, FS & Doherty, P (2003) The FGF receptor uses the endocannabinoid signaling system to couple to an axonal growth response. J Cell Biol 160, 481486.
51. Tanimura, A, Yamazaki, M & Hashimotodani, Y et al. (2010) The endocannabinoid 2-arachidonoylglycerol produced by diacylglycerol lipase alpha mediates retrograde suppression of synaptic transmission. Neuron 65, 320327.
52. Gao, Y, Vasilyev, DV, Goncalves, MB et al. (2010) Loss of retrograde endocannabinoid signaling and reduced adult neurogenesis in diacylglycerol lipase knock-out mice. J Neurosci 30, 20172024.
53. Savinainen, JR, Saario, SM & Laitinen, JT (2012) The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors. Acta Physiol 204, 267276.
54. Wilson, RI & Nicoll, RA (2002) Neuroscience – endocannabinoid signaling in the brain. Science 296, 678682.
55. Diana, MA & Marty, A (2004) Endocannabinoid-mediated short-term synaptic plasticity: depolarization-induced suppression of inhibition (DSI) and depolarization-induced suppression of excitation (DSE). Br J Pharmacol 142, 919.
56. Wilson, RI & Nicoll, RA (2001) Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 410, 588592.
57. Wilson, RI, Kunos, G & Nicoll, RA (2001) Presynaptic specificity of endocannabinoid signaling in the hippocampus. Neuron 31, 453462.
58. Diana, MA, Levenes, C, Mackie, K et al. (2002) Short-term retrograde inhibition of GABAergic synaptic currents in rat Purkinje cells is mediated by endogenous cannabinoids. J Neurosci 22, 200208.
59. Rodríguez de Fonseca, F, Del Arco, I, Bermudez-Silva, FJ et al. (2005) The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol 40, 214.
60. Fowler, CJ (2012) Anandamide uptake explained? Trends Pharmacol Sci 33, 181185.
61. Giang, DK & Cravatt, BF (1997) Molecular characterization of human and mouse fatty acid amide hydrolases. Proc Natl Acad Sci USA 94, 22382242.
62. Maurelli, S, Bisogno, T, De Petrocellis, L et al. (1995) Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma ‘anandamide amidohydrolase’. FEBS Lett 377, 8286.
63. Saghatelian, A, Trauger, SA, Want, EJ et al. (2004) Assignment of endogenous substrates to enzymes by global metabolite profiling. Biochem 43, 1433214339.
64. Cravatt, BF, Giang, DK, Mayfield, SP et al. (1996) Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384, 8387.
65. McKinney, MK & Cravatt, BF (2003) Evidence for distinct roles in catalysis for residues of the serine-serine-lysine catalytic triad of fatty acid amide hydrolase. J Biol Chem 278, 3739337399.
66. Desarnaud, F, Cadas, H & Piomelli, D (1995) Anandamide amidohydrolase activity in rat brain microsomes – identification and partial characterization. J Biol Chem 270, 60306035.
67. Katayama, K, Ueda, N, Kurahashi, Y et al. (1997) Distribution of anandamide amidohydrolase in rat tissues with special reference to small intestine. Biochim Biophys Acta 1347, 212218.
68. Sun, YX, Tsuboi, KU, Zhao, LY et al. (2005) Involvement of N-acylethanolamine-hydrolyzing acid amidase in the degradation of anandamide and other N-acylethanolamines in macrophages. Biochim Biophys Acta 1736, 211220.
69. Reilly, SJ, O'Shea, EM, Andersson, U et al. (2007) A peroxisomal acyltransferase in mouse identifies a novel pathway for taurine conjugation of fatty acids. FASEB J 21, 99107.
70. Wei, BQQ, Mikkelsen, TS, McKinney, MK et al. (2006) A second fatty acid amide hydrolase with variable distribution among placental mammals. J Biol Chem 281, 3656936578.
71. Ueda, N, Yamanaka, K, Terasawa, Y et al. (1999) An acid amidase hydrolyzing anandamide as an endogenous ligand for cannabinoid receptors. FEBS Lett 454, 267270.
72. Ueda, N, Yamanaka, K & Yamamoto, S (2001) Purification and characterization of an acid amidase selective for N-palmitoylethanolamine, a putative endogenous anti-inflammatory substance. J Biol Chem 276, 3555235557.
73. Tsuboi, K, Sun, YX, Okamoto, Y et al. (2005) Molecular characterization of N-acylethanolamine-hydrolyzing acid amidase, a novel member of the choloylglycine hydrolase family with structural and functional similarity to acid ceramidase. J Biol Chem 280, 1108211092.
74. Wang, J, Zhao, LY, Uyama, T et al. (2008) Amino acid residues crucial in pH regulation and proteolytic activation of N-acylethanolamine-hydrolyzing acid amidase. Biochim Biophys Acta 1781, 710717.
75. Blankman, JL, Simon, GM & Cravatt, BF (2007) A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem Biol 14, 13471356.
76. Goparaju, SK, Ueda, N, Taniguchi, K et al. (1999) Enzymes of porcine brain hydrolyzing 2-arachidonoylglycerol, an endogenous ligand of cannabinoid receptors. Biochem Pharmacol 57, 417423.
77. Labar, G, Wouters, J & Lambert, DM (2010b) A review on the monoacylglycerol lipase: at the interface between fat and endocannabinoid signalling. Curr Med Chem 17, 25882607.
78. Bertrand, T, Auge, F, Houtmann, J et al. (2010) Structural basis for human monoglyceride lipase inhibition. J Mol Biol 396, 663673.
79. Karlsson, M, Contreras, JA, Hellman, U et al. (1997) cDNA cloning, tissue distribution, and identification of the catalytic triad of monoglyceride lipase. Evolutionary relationship to esterases, lysophospholipases, and haloperoxidases. J Biol Chem 272, 2721827223.
80. Labar, G, Bauvois, C, Borel, F et al. (2010a) Crystal structure of the human monoacylglycerol lipase, a key actor in endocannabinoid signaling. Chembiochem 11, 218227.
81. Kano, M, Ohno-Shosaku, T, Hashimotodani, Y et al. (2009) Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89, 309380.
82. Navia-Paldanius, D, Savinainen, JR & Laitinen, JT (2012) Biochemical and pharmacological characterization of human alpha/beta-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12). J Lipid Res 53, 24132424.
83. Marrs, WR, Blankman, JL, Horne, EA et al. (2010) The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-AG at cannabinoid receptors. Nature Neurosci 13, 951–U67.
84. Fiskerstrand, T, Brahim, DHB, Johanssond, S et al. (2010) Mutations in ABHD12 cause the neurodegenerative disease PHARC: an inborn error of endocannabinoid metabolism. Am J Hum Genet 87, 410417.
85. Yates, ML & Barker, EL (2009) Inactivation and biotransformation of the endogenous cannabinoids anandamide and 2-arachidonoylglycerol. Mol Pharmacol 76, 1117.
86. Piscitelli, F & Di Marzo, V (2012) ‘Redundancy’ of endocannabinoid inactivation: new challenges and opportunities for pain control. ACS Chem Neurosci 3, 356363.
87. Yu, M, Ives, D & Ramesha, CS (1997) Synthesis of prostaglandin E-2 ethanolamide from anandamide by cyclooxygenase-2. J Biol Chem 272, 2118121186.
88. Di Marzo, V (1998) ‘Endocannabinoids’ and other fatty acid derivatives with cannabimimetic properties: biochemistry and possible physiopathological relevance. Biochim Biophys Acta 1392, 153175.
89. Williams, CM, Rogers, PJ & Kirkham, TC (1998) Hyperphagia in pre-fed rats following oral D9-THC. Physiol Behav 65, 343346.
90. Williams, CM & Kirkham, TC (2002) Observational analysis of feeding induced by delta(9)-THC and anandamide. Physiol Behav 76, 241250.
91. Gamage, TF & Lichtman, AH (2012) The endocannabinoid system: role in energy regulation. Pediatr Blood Cancer 58, 144148.
92. Matias, I & Di Marzo, V (2007) Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 18, 2737. Epub 2006 Dec 1. Review.
93. Li, C, Jones, PM & Persaud, SJ (2011) Role of the endocannabinoid system in food intake, energy homeostasis and regulation of the endocrine pancreas. Pharmacol Ther 129, 307320.
94. Salamone, JD, McLaughlin, PJ, Sink, K et al. (2007) Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol Behav 91, 383388.
95. Di Marzo, V, Goparaju, SK, Wang, L et al. (2001) Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 410, 822825.
96. Wiley, JL, Burston, JJ, Leggett, DC et al. (2005) CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br J Pharmacol 145, 293300.
97. Cota, D (2007) CB1 receptors: emerging evidence for central and peripheral mechanisms that regulate energy balance, metabolism, and cardiovascular health. Diabetes Metab Res Rev 23, 507517.
98. Ravinet Trillou, C, Arnone, M, Delgorge, C et al. (2003) Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 284, R345R353.
99. Vickers, SP, Webster, LJ, Wyatt, A et al. (2003) Preferential effects of the cannabinoid CB, receptor antagonist, SR 141716, on food intake and body weight gain of obese (fa/fa) compared to lean Zucker rats. Psychopharmacology 167, 103111.
100. Ravinet Trillou, C, Delgorge, C, Menet, C et al. (2004) CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 28, 640648.
101. Osei-Hyiaman, D, Harvey-White, J, Batkai, S et al. (2006) The role of the endocannabinoid system in the control of energy homeostasis. Int J Obes 30, S33S38.
102. Bensaid, M, Gary-Bobo, M, Esclangon, A et al. (2003) The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Molecul Pharmacol 63, 908914.
103. Matias, I, Gonthier, MP, Orlando, P et al. (2006) Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 91, 31713180.
104. Fernandez, JR & Allison, DB (2004) Rimonabant Sanofi-Synthélabo. Curr Opin Investig Drugs 5, 430435.
105. Silvestri, C & Di Marzo, V (2013) The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab 17, 475490.
106. Bisogno, T, Burston, JJ, Rai, R et al. (2009) Synthesis and pharmacological activity of a potent inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol. ChemMedChem 4, 946950.
107. Naughton, SS, Mathai, ML, Hryciw, DH et al. (2013) Fatty acid modulation of the endocannabinoid system and the effect on food intake and metabolism. Int J Endocrinol 2013, 361895.


Related content

Powered by UNSILO

PUFA-derived endocannabinoids: an overview

  • Maria Grazia Cascio (a1)


Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.